The Vaccine Safety Initiative

What The Vaccine Safety Initiative does

The Vaccine Safety Initiative (ViVI) is a non-profit research organization founded in 2008 and registered as an e.V. in Berlin, Germany and as a 501(c)(3) in New Orleans, USA. The organization develops and disseminates mobile health (mHealth) applications and digital surveillance tools for vaccine safety monitoring, infectious disease tracking, and adverse event detection at the point of care. Its core products include the ViVI ScoreApp (a disease severity score validated in 8,000+ patients across European academic hospitals and US ICUs), VACC TOOL 2.0 (an automated case classification tool for 14+ neuroinflammatory adverse event definitions with full CDISC compliance), VAccApp (a chatbot vaccination record tracker developed with HPI School of Design Thinking), VIVI HealthSurvey (a 20-language health needs chatbot for displaced populations), and the PEDSIDEA digital surveillance network. All tools combine clinical data capture with machine learning and data science capabilities, targeted at hospital systems, community clinics, public health agencies, clinical researchers, and consumers.

ViVI operates as an international scientific Think Tank with 20+ expert members and 20+ Young ViVI members spanning 15+ countries on 4 continents, including partnerships with the Robert Koch Institute, WHO-Europe (i-Move-Flu Network), GloPID-R, ISARIC, the European Academy of Paediatrics, the HPI School of Design Thinking, and the ImmuHubs EU consortium. The organization generates revenue through research grants, collaborative research agreements, and institutional partnerships rather than commercial product sales, with no publicly disclosed pricing. Tools are distributed via app stores and browser-based access for consumer-facing applications, and through collaborative research agreements for institutional deployments such as the ScoreApp. The initiative has been featured in high-impact peer-reviewed journals (Lancet Global Health, EBioMedicine, Expert Review of Vaccines) and earned media including the CNN documentary 'Unseen Enemy.' Co-founder Prof. Barbara Rath serves as Chair; co-founder Prof. Gerhard Gaedicke passed away in April 2017.

Name

The Vaccine Safety Initiative

Legal name

Vaccine Safety Initiative e.V.

Website

https://vi-vi.org

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

1–10 employees

Short description

Non-profit research organization founded in 2008 that develops mobile health applications and digital surveillance tools for vaccine safety, infectious disease severity scoring, and adverse event detection, serving hospitals, clinics, public health agencies, and displaced populations across 15+ countries.

Ownership category

akta.pro rank

Product category

Digital Health Research

NAICS

Administration of Public Health Programs (92312), Health Care and Social Assistance (62)

SIC

Services-Health Services (8000), Services-Computer Programming Services (7371)

akta.pro primary industry

Vaccine Safety Surveillance & Adverse Event Reporting (AEFI/Pharmacovigilance) (HLAJAHAG)

akta.pro secondary industries

Safety/Pharmacovigilance (PV) & Clinical Safety Systems (HLACAOAH), Vaccine Quality, Safety & Pharmacovigilance (HLAIAEAL), Vaccine-Preventable Disease Surveillance & Coverage Monitoring (HLAJABAK), Immunization & Vaccine Delivery Programs (BPADAIAB)

Keywords

• Vaccine safety research
• Mobile health applications
• Infectious disease surveillance
• Digital health tools
• Public health research

Headquarters

HQ city

Berlin-müggelheim

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Non-profit Research Organization: ViVI operates as a registered non-profit research organization (e.V. in Germany, 501(c)(3) in the USA). Revenue is generated through research grants, collaborative research agreements, and institutional partnerships rather than product sales.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

The Vaccine Safety Initiative (ViVI) develops and deploys proprietary mobile health (mHealth) applications and digital surveillance tools for vaccine safety monitoring, infectious disease tracking, and adverse event detection at the point of care. Its core products include VAccApp for vaccination record tracking, VIVI ScoreApp for disease severity scoring, VIVI HealthSurvey for refugee and migrant health assessment, and VACC TOOL 2.0 for clinical case classification of neuroinflammatory adverse events. The tools are made available to healthcare providers, hospitals, public health agencies, and researchers through collaborative research agreements and app marketplaces, supported by grant funding and institutional partnerships.

Product overview

The Vaccine Safety Initiative (ViVI) offers a portfolio of mobile health applications and scientific collaboration platforms focused on vaccine safety research and infectious disease surveillance. The core products include VACC TOOL 2.0 for clinical case classification of adverse events, VAccApp for vaccination record tracking, VIVI HealthSurvey for migrant health assessment, and VIVI ScoreApp for disease severity scoring. These applications are supported by the ViVI Think Tank, an international scientific forum, and implemented through research programs like PEDSIDEA. The organization uses Design Thinking methodology combined with scientific validation to develop and iterate its digital health tools.

Differentiator

Problem solved

Functional benefit

Brands

• VAccApp: A mobile application chatbot to help patients keep vaccination records straight and understand their vaccination status.
• VIVI HealthSurvey
• VIVI ScoreApp
• VACC TOOL
• GoodImmunity

Products and services

• VACC TOOL 2.0 (ViVI Automated Case Classification Tool) A mobile application enabling physicians to classify clinical cases according to 14+ pre-defined case definitions for neuroinflammatory adverse events (NIAE). Used for instant case classification and longitudinal follow-up at point-of-care, fully compliant with CDISC data standards.
• VIVI VAccApp A chatbot mobile application helping patients and families track vaccination records and understand their immunization status. Users are guided through vaccine preventable diseases with selectable VIVI avatars. Available in App Store, Google Play, and browser.
• VIVI HealthSurvey A validated health survey tool for migrants and refugees available as a chatbot in 20 languages including English, Spanish, French, German, Russian, Farsi, and Arabic. Covers basic symptoms, environmental exposures, psychological assessments, access to healthcare and immunizations.
• VIVI ScoreApp (ViVI Disease Severity Score) A mobile app for iOS and Android that scores disease severity for influenza-like illness and respiratory infections across pediatric and adult populations. Used in hospitals, clinics, and by patients at home for better care and resource allocation. Validated in more than 8,000 patients at major academic hospitals in Europe.
• ViVI ScoreMe Patient-facing component of PEDSIDEA allowing citizens to track their own symptoms and those of family members, particularly during pandemics.
• ViVI Scientific Think Tank An international interdisciplinary scientific forum bringing together experts in infectious diseases, immunology, medical anthropology, risk communication, machine learning, and data science to promote evidence-based vaccine safety research and collaboration.
• PEDSIDEA (Partnering for Enhanced Digital Surveillance of Influenza-like Disease and the Effect of Antivirals & Vaccines) A digital surveillance network implemented across hospitals, community clinics, and homes to monitor influenza-like disease, vaccine effectiveness, and antiviral effects using ViVI ScoreApp.
• GOODIMMUNITY A program launched to facilitate research on immunological phenomena related to COVID-19 including antibody-dependent enhancement and post-infectious adverse events such as ADEM, Guillaume Barré Syndrome, and Bell's Palsy.
• SEKI (Strengthening Education and Knowledge on Immunisation) An educational initiative in collaboration with the European Academy of Paediatrics to improve vaccine safety communication and training during medical school and beyond.

Quantifiable outcome

• The ViVI Score has been validated in more than 8,000 patients at major academic hospitals in Europe and is now used in community clinics and ICUs in the USA
• +4 more outcomes

Named customers8 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

Eleven partnerships are on record, tiered core and secondary.

• Robert Koch InstitutecoreStrategic or Co-development PartnerViVI collaborates with the Robert Koch Institute (Germany's central public health institution) on prospective surveillance programs for influenza-like illness and meningitis/encephalitis in children. Joint work has produced large cohort studies (6,000 patients) capturing up to 1,600 data points per patient, and quality improvement programs for vaccine-preventable disease surveillance.
• HPI School of Design Thinking (University of Potsdam, Germany)coreStrategic or Co-development PartnerThe Advanced Track Design Thinking Project in collaboration with the HPI School of Design Thinking resulted in the development of key mobile health tools including VAccApp. This partnership applies the Design Thinking innovation methodology to vaccine safety communication challenges, with the concept published in Current Drug Safety.
• GloPID-R (Global Research Collaboration for Infectious Disease Preparedness)coreStrategic or Co-development PartnerViVI participated in a GloPID-R meeting in London, UK two weeks prior to the WHO's COVID-19 outbreak announcement, brainstorming how the world could better prepare for a global pandemic. ViVI continues collaborating with GloPID-R on pandemic preparedness and outbreak response research coordination.
• ISARIC (International Severe Acute Respiratory and Emerging Infection Consortium)coreStrategic or Co-development PartnerViVI participated in the ISARIC annual meeting during the last week of February 2020 as a Public Health Emergency of International Concern was already underway, contributing expertise to global COVID-19 response coordination.
• WHO-Europe / i-Move-Flu NetworkcoreStrategic or Co-development PartnerViVI coordinates the PEDSIDEA project within the i-Move-Flu project, a vaccine effectiveness network funded by WHO-Europe, with activities at University Hospitals (CHU) in Besançon and Dijon, France.
• ImmuHubs ConsortiumcoreStrategic or Co-development PartnerViVI is featured on the ImmuHubs Website (immunisationhubs.eu), an EU-funded technology platform project. The VIVI HealthSurvey chatbot and other ViVI tools are promoted through this platform for immunization research across Europe.
• CDISC (Clinical Data Interchange Standards Consortium)coreTechnology or IntegrationBron Kisler, a ViVI founding member, is Co-Founder of CDISC. ViVI ensures full compliance with CDISC data standards for all digital tools, enabling interoperability with regulatory agencies and clinical research data systems globally.
• SEKI (Strengthening Education and Knowledge on Immunisation)coreStrategic or Co-development PartnerSEKI is a collaboration between ViVI and the European Academy of Paediatrics, focused on strengthening vaccine education and knowledge among medical students and practicing pediatricians. Educational concepts from ViVI's Vaccine Safety Training Initiative formed the foundation for this program.
• National Child Traumatic Stress NetworksecondaryStrategic or Co-development PartnerThe VIVI HealthSurvey incorporates a validated psychological questionnaire provided by the National Child Traumatic Stress Network, supporting mental health assessment for children and families displaced by natural disasters or armed conflict.
• International Organization for Migration (IOM)secondaryStrategic or Co-development PartnerThe ViVI HealthSurvey project is featured on the Migration Research Portal of the UN Institute of Migration (IOM), documenting use of the digital health tool during the 2015-2016 refugee crisis in Europe.
• City of Vienna (Municipal Government)secondaryStrategic or Co-development PartnerViVI collaborated with the City of Vienna to survey 1,000 parents picking up children from kindergarten, investigating vaccine safety perceptions and attitudes among parents in Austria.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• HealthMap (Boston Children's Hospital): HealthMap is a digital disease-surveillance platform aggregating open-source data for real-time outbreak monitoring. Comparable to ViVI because both provide real-time digital surveillance of infectious diseases for public-health agencies, though HealthMap focuses on web/news signals rather than point-of-care clinical data.
• Sickweather: Sickweather uses crowdsourced and social-data signals to forecast illness outbreaks. Comparable to ViVI as a digital surveillance peer for influenza-like illness and respiratory disease tracking, though Sickweather relies on consumer signals rather than validated clinical scoring.
• EpiVax: EpiVax is a vaccine-immunogenicity and predictive-immunology company using computational tools to assess vaccine safety and efficacy. Comparable to ViVI's computational and immunology expertise applied to vaccine safety and AEFI classification (VACC TOOL).
• Airfinity: Airfinity provides infectious disease and vaccine intelligence, including disease forecasting and vaccine effectiveness data. Comparable to ViVI because both deliver infectious-disease surveillance and vaccine-related data products to public health and pharma stakeholders.
• BlueDot: BlueDot is a commercial infectious-disease intelligence platform that uses data analytics and surveillance to track and forecast outbreaks globally. It is comparable to ViVI as both organizations operate at the intersection of public-health surveillance, pandemic preparedness, and digital disease-tracking tools.
• Metabiota (now BlueDot after acquisition): Metabiota built a pandemic-risk intelligence platform tracking infectious disease outbreaks. Comparable to ViVI's epidemiological surveillance work for vaccine-preventable diseases and pandemic preparedness, though operating with a commercial analytics model.

Broad incumbents

• IQVIA: IQVIA is a global clinical research and pharmacovigilance services provider offering vaccine safety and post-marketing surveillance. Comparable to ViVI because both operate in vaccine pharmacovigilance, AEFI reporting, and clinical-trial endpoint standardization — though IQVIA is a much larger commercial CRO/technology provider.
• Oracle Health (formerly Cerner): Oracle Health offers clinical and population-health platforms including surveillance and immunization registry functionality. Comparable to ViVI as a digital health platform addressing disease surveillance and immunization data, though Oracle Health is a broad incumbent serving entire health systems rather than vaccine-specific surveillance.
• Veeva Systems: Veeva provides cloud software for life sciences including clinical data, regulatory, and safety/pharmacovigilance applications. Comparable to ViVI because both serve vaccine and clinical-trial data interoperability needs, though Veeva is a large commercial platform serving the broader pharma industry.
• GISAID (Global Initiative on Sharing All Influenza Data): GISAID operates a major global data-sharing platform for influenza and COVID-19 virus data used by public health agencies and researchers. Comparable to ViVI as a public-health-data infrastructure layer for vaccine-preventable disease surveillance, though GISAID focuses on pathogen genomic data rather than clinical severity scoring.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/_vaccinesafety
• LinkedInlinkedin.com/company/vaccinesafety

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Vaccine Safety Initiative